PHIA Koninklijke Philips N.V.

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies

September 11, 2025

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-generation patient monitoring solutions. This expanded agreement reflects our commitment to empower clinicians with smarter, more integrated technologies that support better outcomes across the continuum of care.

Accelerating access to next-generation monitoring technologies 

At the heart of the expanded partnership is a joint effort to integrate Masimo’s advanced monitoring technologies – including SET® pulse oximetry, Radius PPG, and a range of sensor technology – into Philips’ multi-parameter patient monitoring platforms. This integration supports clinicians with reliable data and actionable insights across bedside monitors, central stations, and wearable solutions, while giving them the flexibility to use their preferred measurement technologies within a single, unified system. By embedding these capabilities into Philips’ monitoring ecosystem, the collaboration aims to reduce complexity, enhance interoperability, and deliver streamlined tools that support timely decision-making and continuity of care. 

 

Building on this foundation, Philips and Masimo also plan to collaborate on the development and co-promotion of next-generation monitoring solutions that reflect emerging clinical needs and evolving market demands such as the need for greater patient mobility. These efforts are focused on advancing smart, connected care and expanding access to innovative technologies, including AI algorithms, that have the potential to improve patient care over time. 

 

“Our priority is helping clinicians deliver the best possible care to their patients, and that means staying ahead of the curve,” said Julia Strandberg, Executive Vice President and Business Leader Connected Care at Royal Philips. “This partnership allows us to respond quickly to evolving clinical needs and market trends, integrating proven technologies into solutions that are easy to use, reliable, and scalable.”

“We are excited to continue to partner with Philips to bring Masimo’s newest innovations in wearables and artificial intelligence to Philips’ platforms,” said Katie Szyman, CEO of Masimo. “Expanding our strong, long-standing partnership with Philips allows us to build on our shared legacies of innovation and helps ensure that Masimo’s best-in-class technologies reach even more patients. Together, Masimo and Philips will continue to empower clinicians to transform patient care.”

A shared commitment to innovation and impact 

The renewed partnership underscores both companies’ dedication to transforming patient care through meaningful innovation. By bringing together Philips’ deep expertise in patient monitoring and Masimo’s advanced noninvasive technologies, the collaboration is focused on delivering integrated, clinically validated solutions that scale to meet the needs of healthcare providers. It also aligns with Philips’ broader strategy to work with industry-leading partners to enhance care delivery, improve operational efficiency, and support vendor-neutral interoperability across healthcare systems.

For further information, please contact:

Mark Groves

External Relations, Philips

Tel:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at

Attachment



EN
11/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch